Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

GlobeNewswire September 27, 2019

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 26, 2019

Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

GlobeNewswire September 18, 2019

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

GlobeNewswire September 16, 2019

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019

GlobeNewswire September 5, 2019

Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome

GlobeNewswire September 4, 2019

Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates

GlobeNewswire August 7, 2019

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019

GlobeNewswire August 2, 2019

Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

GlobeNewswire July 31, 2019

Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome

GlobeNewswire July 29, 2019

Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer's Association International Conference (AAIC)

GlobeNewswire July 17, 2019

Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome

GlobeNewswire June 25, 2019

Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)

GlobeNewswire June 6, 2019

Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome

GlobeNewswire May 8, 2019

Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results and Provides Clinical Study Updates

GlobeNewswire May 8, 2019

Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019

GlobeNewswire May 6, 2019

Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference

GlobeNewswire April 5, 2019

Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting

GlobeNewswire March 28, 2019

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

Business Wire March 20, 2019

Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.

GlobeNewswire March 18, 2019